Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:51:04.257Z.
Calculation as of: 2026-10-06T18:51:04.257Z.
Quote observation: 2026-10-06T18:50:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3328ed161ff00c537a80d7dceb604f662f1c22c4e65cb57a824bf36ce3bbbe60
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Corvus Pharmaceuticals, Inc.
Market Cap
$880.85M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$882.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$882.99M
EV/EBITDA Ratio
5.89x
TTM Avg
5.93x
3Y Avg
5.93x
5Y Avg
5.93x
Market Cap
$863.59M
EV/EBITDA Ratio
9.39x
TTM Avg
6.28x
3Y Avg
11.56x
5Y Avg
11.56x
Market Cap
$849.50M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$912.77M
EV/EBITDA Ratio
12.52x
TTM Avg
10.56x
3Y Avg
12.81x
5Y Avg
13.69x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $880.85M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $882.10M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $882.99M | 5.89x | 5.93x | 5.93x | 5.93x |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $863.59M | 9.39x | 6.28x | 11.56x | 11.56x |
| SL Science Holding Ltd (SLBT)vs › | $857.96M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $898.60M | 10.58x | 9.34x | 18.56x | 25.76x |
| SI-BONE, Inc. (SIBN)vs › | $856.66M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $849.50M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $912.77M | 12.52x | 10.56x | 12.81x | 13.69x |
| QuidelOrtho Corporation (QDEL)vs › | $846.74M | N/A | 19.31x | 12.44x | 8.61x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
